Nxera Pharma Future Growth
Future criteria checks 4/6
Nxera Pharma is forecast to grow earnings and revenue by 52.9% and 17.7% per annum respectively. EPS is expected to grow by 44.3% per annum. Return on equity is forecast to be 9.5% in 3 years.
Key information
52.9%
Earnings growth rate
44.3%
EPS growth rate
| Pharmaceuticals earnings growth | 12.6% |
| Revenue growth rate | 17.7% |
| Future return on equity | 9.5% |
| Analyst coverage | Good |
| Last updated | 08 Apr 2024 |
Recent future growth updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 44,550 | 6,330 | 10,459 | 9,049 | 8 |
| 12/31/2025 | 38,941 | 3,470 | 7,921 | 5,138 | 8 |
| 12/31/2024 | 35,223 | 951 | 3,295 | 4,107 | 9 |
| 12/31/2023 | 12,766 | -7,193 | -6,124 | -5,273 | N/A |
| 9/30/2023 | 12,402 | -3,378 | 38 | 653 | N/A |
| 6/30/2023 | 15,258 | 1,860 | 9,821 | 10,153 | N/A |
| 3/31/2023 | 15,393 | 1,050 | 10,043 | 10,386 | N/A |
| 12/31/2022 | 15,569 | 382 | 9,649 | 9,952 | N/A |
| 9/30/2022 | 22,763 | -383 | 14,534 | 14,836 | N/A |
| 6/30/2022 | 17,046 | -224 | 5,074 | 5,389 | N/A |
| 3/31/2022 | 17,624 | 100 | 6,165 | 6,394 | N/A |
| 12/31/2021 | 17,712 | 1,017 | 6,894 | 7,095 | N/A |
| 9/30/2021 | 7,989 | 1,296 | -589 | -448 | N/A |
| 6/30/2021 | 9,449 | 1,299 | 2,013 | 2,140 | N/A |
| 3/31/2021 | 8,887 | 1,072 | 2,186 | 2,313 | N/A |
| 12/31/2020 | 8,842 | 1,479 | 4,567 | 4,672 | N/A |
| 9/30/2020 | 6,399 | -1,671 | 1,352 | 1,441 | N/A |
| 6/30/2020 | 7,186 | -1,080 | 4,315 | 4,422 | N/A |
| 3/31/2020 | 7,752 | -332 | 4,362 | 4,551 | N/A |
| 12/31/2019 | 9,726 | 1,432 | 3,161 | 3,441 | N/A |
| 12/31/2018 | 3,550 | -6,918 | -8,648 | -6,047 | N/A |
| 9/30/2018 | 3,444 | -5,483 | -7,726 | -5,640 | N/A |
| 6/30/2018 | 5,005 | -4,202 | -5,116 | -3,358 | N/A |
| 3/31/2018 | 6,955 | -2,654 | -3,135 | -2,167 | N/A |
| 12/31/2017 | 8,060 | -2,608 | -147 | 609 | N/A |
| 9/30/2017 | 8,376 | -1,338 | N/A | 211 | N/A |
| 6/30/2017 | 6,603 | -1,547 | N/A | -1,102 | N/A |
| 3/31/2017 | 18,901 | 9,311 | N/A | 12,856 | N/A |
| 12/31/2016 | 17,528 | 6,481 | N/A | 11,424 | N/A |
| 9/30/2016 | 21,450 | 9,514 | N/A | 15,378 | N/A |
| 6/30/2016 | 22,658 | 10,508 | N/A | 17,064 | N/A |
| 3/31/2016 | 8,151 | -1,432 | N/A | 4,471 | N/A |
| 12/31/2015 | 10,461 | 2,599 | N/A | 4,928 | N/A |
| 9/30/2015 | 5,646 | -255 | N/A | 1,503 | N/A |
| 6/30/2015 | 4,010 | -118 | N/A | 929 | N/A |
| 3/31/2015 | 3,671 | 568 | N/A | 92 | N/A |
| 12/31/2014 | 1,169 | 2,191 | N/A | N/A | N/A |
| 9/30/2014 | 1,051 | 1,593 | N/A | 1,079 | N/A |
| 6/30/2014 | 2,236 | 2,030 | N/A | N/A | N/A |
| 3/31/2014 | 2,069 | 1,526 | N/A | 363 | N/A |
| 12/31/2013 | 1,948 | -849 | N/A | N/A | N/A |
| 9/30/2013 | 2,324 | -507 | N/A | 767 | N/A |
| 6/30/2013 | 1,824 | -601 | N/A | N/A | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 4565 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.2%).
Earnings vs Market: 4565 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 4565 is expected to become profitable in the next 3 years.
Revenue vs Market: 4565's revenue (17.7% per year) is forecast to grow faster than the JP market (4.4% per year).
High Growth Revenue: 4565's revenue (17.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 4565's Return on Equity is forecast to be low in 3 years time (9.5%).